Portal de Periódicos da CAPES

An Open Label, Phase I/II Clinical Trial to Evaluate the Safety and Biological Activity of HIV-IT (V) (HIV-1 IIIB env/rev Retroviral Vector) in HIV-1-Infected Subjects. University of California, San Diego, California

1995; Mary Ann Liebert, Inc.; Volume: 6; Issue: 7 Linguagem: Inglês

10.1089/hum.1995.6.7-941

1557-7422

Richard Haubrich, J. Allen McCutchan,

Virus-based gene therapy research

Human Gene TherapyVol. 6, No. 7 News and CommentsAn Open Label, Phase I/II Clinical Trial to Evaluate the Safety and Biological Activity of HIV-IT (V) (HIV-1IIIBenv/rev Retroviral Vector) in HIV-1-Infected Subjects. University of California, San Diego, CaliforniaPRINCIPAL INVESTIGATOR Richard Haubrich and CO-INVESTIGATOR J. Allen McCutchanPRINCIPAL INVESTIGATOR Richard HaubrichSearch for more papers by this author and CO-INVESTIGATOR J. Allen McCutchanSearch for more papers by this authorPublished Online:19 Mar 2008https://doi.org/10.1089/hum.1995.6.7-941AboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail FiguresReferencesRelatedDetailsCited byFusion of Epstein-Barr Virus Nuclear Antigen-1-Derived Glycine–Alanine Repeat to Trans-Dominant HIV-1 Gag Increases Inhibitory Activities and Survival of Transduced Cells In Vivo Diana Hammer, , Jens Wild, Christine Ludwig, Benedikt Asbach, Frank Notka, and Ralf Wagner25 June 2008 | Human Gene Therapy, Vol. 19, No. 6El futuro en la infección por VIH: terapia génica y ARN de interferenciaEnfermedades Infecciosas y Microbiología Clínica, Vol. 23The future of HIV infection: gene therapy and RNA interferenceEnfermedades Infecciosas y Microbiología Clínica, Vol. 23Therapie mit Genen: Erfahrungen und Zukunftsperspektiven 10 Jahre nach ihrer klinischen EinführungAktueller Stand der GentherapieInhibition of Human Immunodeficiency Virus Replication and Growth Advantage of CD4+ T Cells and Monocytes Derived from CD34+ Cells Transduced with an Intracellular Antibody Directed against Human Immunodeficiency Virus Type 1 Tat Mark C. Poznansky, Joyce La Vecchio, Sandra Silva-Arietta, Julie Porter-Brooks, Kate Brody, Ivona T. Olszak, Gregor B. Adams, Urban Ramstedt, Wayne A. Marasco, and David T. Scadden6 July 2004 | Human Gene Therapy, Vol. 10, No. 15Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancerPathology & Oncology Research, Vol. 5, No. 1The Use of Ribozymes in Gene Therapy Approaches to AIDS Volume 6Issue 7Jul 1995 InformationCopyright 1995, Mary Ann Liebert, Inc.To cite this article:PRINCIPAL INVESTIGATOR Richard Haubrich and CO-INVESTIGATOR J. Allen McCutchan.An Open Label, Phase I/II Clinical Trial to Evaluate the Safety and Biological Activity of HIV-IT (V) (HIV-1IIIBenv/rev Retroviral Vector) in HIV-1-Infected Subjects. University of California, San Diego, California.Human Gene Therapy.Jul 1995.941-955.http://doi.org/10.1089/hum.1995.6.7-941Published in Volume: 6 Issue 7: March 19, 2008PDF download